Pricing Log in Create free account
Friday 6 November 2026 Export ALNY’s income statement to Excel — free account

Alnylam Pharmaceuticals, Inc.

ALNY Healthcare Biotechnology

Alnylam Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $3.7 billion, up 65.2% from fiscal 2024.

Revenue
+16.7%
EPS
+747.6%
Free cash flow
−4.76%
Total debt
−2.66%

Quarter to September 2026, against a year earlier

157.21 0.55 +0.35%
Market cap
$21.0B
P/E
7.9×
Fwd P/E
13.5×
Dividend yield
—
F-score
6/9
Altman Z
7.30
Beneish M
−1.95
Dividend safety
n/a
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Valuation Filings

Alnylam Pharmaceuticals, Inc. (ALNY) SEC filings, changes and red flags

Red flags

  • Officer departure

    Alnylam Pharmaceuticals, Inc. reported the departure of an officer or director

    8-K filed · The filing · sec.gov

  • Covenant breach

    Alnylam Pharmaceuticals, Inc.’s 10-Q reports a breach of a debt covenant, or a waiver to avoid one

    The Revolving Credit Agreement contains customary affirmative and negative covenants and conditions to borrowing, as well as customary events of default.

    10-Q filed · The filing · sec.gov

Filings

Form Period Filed What it reports Flags
8-K Nov 2, 2026 5.02 Departure or appointment of directors or officers; 8.01 Other events Officer departure
10-Q Sep 30, 2026 P1I2: 9 added · 6 removed · 22 modified
P2I1A: 4 added · 2 removed · 84 modified
8-K Oct 29, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-Q Jun 30, 2026 P1I2: 7 added · 5 removed · 36 modified
P2I1A: 5 added · 5 removed · 93 modified 		Covenant breach
8-K Jul 30, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K May 20, 2026 5.02 Departure or appointment of directors or officers; 5.07 Submission of matters to a vote of security holders
10-Q Mar 31, 2026
8-K Apr 30, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Mar 2, 2026 5.02 Departure or appointment of directors or officers
10-K Dec 31, 2025 1: 69 added · 52 removed · 119 modified
1A: 69 added · 49 removed · 151 modified
7: 17 added · 15 removed · 36 modified
8-K Feb 12, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Jan 11, 2026 2.02 Results of operations and financial condition
8-K Dec 10, 2025 8.01 Other events; 9.01 Financial statements and exhibits
8-K Dec 2, 2025 5.02 Departure or appointment of directors or officers
10-Q Sep 30, 2025
8-K Oct 30, 2025 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Sep 30, 2025 1.01 Entry into a material definitive agreement; 2.03 Creation of a direct financial obligation; 9.01 Financial statements and exhibits
8-K Sep 12, 2025 1.01 Entry into a material definitive agreement; 2.03 Creation of a direct financial obligation; 3.02 Unregistered sales of equity securities; 8.01 Other events; 9.01 Financial statements and exhibits
8-K Sep 8, 2025 8.01 Other events; 9.01 Financial statements and exhibits
10-Q Jun 30, 2025
8-K Jul 31, 2025 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-Q Mar 31, 2025
10-K Dec 31, 2024
8-K Jan 12, 2025 2.02 Results of operations and financial condition
10-Q Sep 30, 2024
10-Q Jun 30, 2024
8-K Feb 15, 2024 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Jan 7, 2024 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits

From the company’s filings on sec.gov. Red flags are raised by rules over the filings’ own data and text; they are not investment advice.